Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599

被引：2
|
作者：
Sandler, AB
Gray, R
Brahmer, J
Dowlati, A
Schiller, JH
Perry, MC
Johnson, DH
机构：
[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Case Western Reserve Univ, Cleveland, OH 44106 USA
[5] Univ Wisconsin, Madison, WI USA
[6] Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80220-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [21] Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients
    Schmittel, A
    Siehl, JM
    Schulze, M
    Schulze, K
    Thiel, E
    Keilholz, U
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1333 - 1336
  • [22] Phase II study comparing paclitaxel-carboplatin alone with paclitaxel-carboplatin plus bevacizumab in previously untreated Japanese patients with advanced-stage non-squamous non-small cell lung cancer (NSCLC)
    Asahina, Hajime
    Kunitoh, Hideo
    Ichinose, Yukito
    Horai, Takeshi
    Nishiwaki, Yutaka
    Hida, Toyoaki
    Yamamoto, Nobuyuki
    Kawahara, Masaaki
    Saijo, Nagahiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S285 - S285
  • [23] Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
    Kelly, K
    Crowley, J
    Bunn, PA
    Presant, CA
    Grevstad, PK
    Mainpour, CM
    Ramsey, SD
    Wozniak, AJ
    Weiss, GR
    Moore, DF
    Israel, VK
    Livingston, RB
    Gandara, DR
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3210 - 3218
  • [24] Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599
    Dahlberg, S. E.
    Sandler, A. B.
    Brahmer, J. R.
    Schiller, J. H.
    Johnson, D. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)
    Reynolds, C.
    Barrera, D.
    Vu, D. Q.
    Jotte, R.
    Spira, A. I.
    Weissman, C. H.
    Boehm, K. A.
    Ilegbodu, D.
    Pritchard, S.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] CLINICAL PATTERNS AND OUTCOMES FOR THE BEVACIZUMAB MAINTENANCE POPULATION IN THE ECOG E4599 STUDY OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS OF AN EXPLORATORY ANALYSIS
    Sandler, Alan B.
    Byrtek, Michelle
    Fages, Sophie
    Schiller, Joan
    Dowlati, Afshin
    Brahmer, Julie
    Johnson, David H.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1311
  • [27] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Sakamori, Yuichi
    Nagai, Hiroki
    Ozasa, Hiroaki
    Kaneda, Toshihiko
    Yoshioka, Hiroshige
    Nakagawa, Hiroaki
    Tomii, Keisuke
    Okada, Asuka
    Yoshimura, Kenichi
    Hirabayashi, Masataka
    Hirai, Toyohiro
    ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
  • [28] Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003
    Williamson, SK
    Crowley, JJ
    Lara, PN
    McCoy, J
    Lau, DHM
    Tucker, RW
    Mills, GM
    Gandara, DR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9097 - 9104
  • [29] A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
    Kelly, K
    Pan, ZX
    Murphy, J
    Huffman, DH
    Bunn, PA
    CLINICAL CANCER RESEARCH, 1997, 3 (07) : 1117 - 1123
  • [30] A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Blumenschein, G
    Jotte, R
    von Pawel, J
    Miller, W
    Khuri, F
    Rigas, J
    Mabry, M
    Dziewanowska, Z
    Negro-Vilar, A
    LUNG CANCER, 2005, 49 : S31 - S31
12345